Table 2. Results of the included case-control studies on the association between toxocariasis and epilepsy.

References	PWE, n	PWOE, n	Seropositivity in PWE, n (%)	Seropositivity in PWOE, n (%)	A priori statistical power, %*	A posteriori statistical power, %	OR (95% CI)	p-value
Glickman et al., J Pediatr 1979 [30]	84	108	19 (22.6)	11 (10.2)	33.6	65.3	2.58 (1.15–5.77)	0.018
Arpino et al., Epilepsia 1990 [31]	91	214	20 (21.9)	26 (12.1)	40.1	59.3	2.04 (1.07–3.88)	0.028
Nicoletti et al., Neurology 2002 [35]	113	233	28 (24.8)	28 (12.0)	47.6	85.0	2.41 (1.35–4.31)	0.002
Akyol et al., Seizure 2007 [41]	100	50	12 (12.0)	4 (8.0)	32.8	11.3	1.57 (0.48–5.14)	0.4
Nicoletti et al., Epilepsia 2007 [36]	191	191	114 (59.7)	97 (50.8)	90.9	41.0	1.43 (0.96–2.15)	0.08
Nicoletti et al., Epilepsia 2008 [37]	231	201	38 (16.4)	13 (6.5)	55.8	89.6	2.85 (1.47–5.51)	0.001
Winkler et al., Trans R Soc Trop Med Hyg. 2008 [38]	40	20	19 (47.5)	8 (40.0)	33.5	8.0	1.36 (0.46–4.03)	0.58

^*Statistical power assuming an odds ratio equal to 2 with a type I error equal to 5% and one control per case.

OR, crude odds ratio; PWE, people with epilepsy as cases; PWOE, people without epilepsy as controls; seropositivity, presence of antibodies anti-Toxocara spp.; 95% CI, 95% confidence interval.